Welcome to the e-CCO Library!

P571: Vedolizumab (VDZ) real-world outcomes in ulcerative colitis (UC)
Year: 2018
Source: ECCO '18 Vienna
Authors:

S.S.R. Pulusu1*, A. Srinivasan2, K. Krishnaprasad3, D. Cheng4, T. Mogilevski5, E. Flanagan6, C. Keung7, C. Wu8, R. Prosser9, E. Sawyer10, Q.-U.-A. Rizvi11, H. Su12, W.-K. Leung13, A. Edmundson3, S. Cooke14, G. Mahy14, L. Thin15, G. Radford-Smith16, M. Sparrow12, J.M. Andrews11, S. Connor10, P. Bampton17, S. Ghaly8, D. Van Langenberg7, S. Bell6, P. De Cruz5, J. Begun4, S. Ng18, S. Travis2, I. Lawrance1

Created: Thursday, 21 February 2019, 9:14 AM
P572 Clinical outcomes after discontinuation of anti-tumour necrosis factor-α agents in inflammatory bowel disease patients with clinical remission: KASID multicenter study
Year: 2020
Source:

ECCO'20 Vienna

Authors:

J.H. Song1, S.M. Kong1, J. Shin1, G. Seong1, E.A. Kang2, S.K. Park3, S.N. Hong1, Y.S. Kim4, K.B. Bang5, K.O. Kim6, H.S. Lee7, S.B. Kang8, S.Y. Shin9, E.M. Song10, C.H. Choi9, T.J. Kim1, E.R. Kim1, D.K. Chang1, Y.H. Kim1

Created: Thursday, 30 January 2020, 10:12 AM
P572: Coexisting Inflammatory bowel disease and Ankylosing spondylitis: Management and clinical outcomes
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Savin, E.(1)*;Levartovsky, A.(2);Gendelman, O.(3);Lidar, M.(3);Ben-Horin, S.(2);Kopylov, U.(2);
Created: Friday, 14 July 2023, 11:05 AM
P572: Half of children with acute severe colitis have predominant single faecal bacterial species, mostly Escherichia coli: Microbiome results from the PRASCO trial
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

J. Bishai1, G. Abitbol2, G. Focht2, M. Schirmer1, D. Marcus2, B. Yerushalmi3, M. Aloi4, A. M. Griffiths5, L. Albenberg1, K-L. Kolho6, S. Cohen7, A. Assa8, A. Levine9, H. Vlamakis1, R. Xavier1, D. Turner*2

Created: Friday, 22 February 2019, 9:41 AM
P572: Medical therapies for stricturing Crohn's disease: efficacy and cross-sectional imaging predictors of therapeutic failure
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Campos C.1, Perrey A.2, Lambert C.3, Pereira B.3, Goutte M.1,4, Goutorbe F.1,5, Dubois A.6, Reymond M.1, Allimant C.1, Dapoigny M.1, Bommelaer G.1,4, Hordonneau C.2, Buisson A.*1,4

Created: Wednesday, 20 February 2019, 10:36 AM
P572: Reactive dose escalation of infliximab in patients with Crohn’s disease in TAILORIX leads to improved outcomes
Year: 2018
Source: ECCO '18 Vienna
Authors:

E. Dreesen1*, D. Laharie2, G. Lambrecht3, P. Bossuyt4, A. Buisson5, J. Filippi6, P. Van Hootegem7, G. D'Haens8, S. Vermeire9,10, A. Gils1

Created: Thursday, 21 February 2019, 9:14 AM
P572: The influence of beliefs about medication in therapeutic adherence among patients with inflammatory bowel disease.
Year: 2021
Source: ECCO'21 Virtual
Authors: De Castro Parga, M.L.(1,2);Alvarez-Smith, C.(1);Sanroman, L.(1);Figueira, M.(1);Hernández, V.(1);Pineda, J.(1);Martinez-Cadilla, J.(1);Pereira, S.(1);Rodriguez-Prada, I.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P572: Therapy optimisation and intravenous ferric carboxymaltose in active or inactive IBD with iron deficiency: it's time to make iron deficiency part of tight monitoring to reach T2T? – preliminary results of a prospective study
Year: 2022
Source: ECCO'22
Authors: Molnár, T.(1);Resál, T.(1);Bacsur, P.(1);Rutka, M.(1);Szántó, K.(1);Bálint, A.(1);Milassin, Á.(1);Fábián, A.(1);Bor, R.(1);Szepes, Z.(1);Farkas, K.(1);
Created: Friday, 11 February 2022, 3:56 PM
P573 Frequency and effectiveness of empirical anti-TNF dose intensification in inflammatory bowel disease: an on-going systematic review with meta-analysis
Year: 2020
Source:

ECCO'20 Vienna

Authors:

L. Guberna Blanco, O.P. Nyssen, M. Chaparro, J.P. Gisbert

Created: Thursday, 30 January 2020, 10:12 AM
P573: Change in fatigue in patients with Ulcerative Colitis or Crohn's disease initiating vedolizumab or other biologic therapy: Data from Belgian registry patients
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Louis, E.(1)*;Bossuyt, P.(2);Colard, A.(3);Caenepeel, P.(4);Baert, F.(5);Hantson, A.(6);Van Gassen, G.(6);Zhou, J.(7);Vermeire, S.(8);
Created: Friday, 14 July 2023, 11:05 AM
P573: Comparative effectiveness of second-line biological therapies for Ulcerative colitis and Crohn’s disease in patients with prior failure of anti-tumour necrosis factor treatment
Year: 2021
Source: ECCO'21 Virtual
Authors: Hyun, H.K.(1);Yu, J.(1);Kang, E.A.(1);Park, J.(1);Park, S.J.(1);Park, J.J.(1);Kim, T.I.(1);Kim, W.H.(1);Cheon, J.H.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P573: Impact of the duration of combination therapy on clinical and pharmacological efficacy of infliximab in inflammatory bowel diseases
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Vernet C., Roblin X., Williet N.

Created: Wednesday, 20 February 2019, 10:36 AM
P573: Real-world effectiveness and safety of vedolizumab and anti-TNF in biologic-naive ulcerative colitis patients: Results from the EVOLVE study
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

A. Yarur*1, G. Mantzaris2, M. Silverberg3, M. Walshe3, P. Zezos3, D. Stein4, M. Bassel5, T. Lissoos6, C. Lopez6, A. Natsios7, G. Radulescu8, H. Patel9, D. Demuth10, B. Bressler11

Created: Friday, 22 February 2019, 9:41 AM
P573: Safety and immune modulatory properties of etrasimod (APD334), a next-generation oral, selective sphingosine 1-phosphate receptor (S1PR) modulator, in healthy volunteers
Year: 2018
Source: ECCO '18 Vienna
Authors:

L. Peyrin-Biroulet1, J. Adams2, S. Turner2, L. Trokan2, J. Panes3*

Created: Thursday, 21 February 2019, 9:14 AM
P573: The safety profile of upadacitinib maintenance therapy in ulcerative colitis in the Phase 3 U-ACHIEVE study is consistent with that in approved indications
Year: 2022
Source: ECCO'22
Authors: Colombel, J.F.(1);Panaccione, R.(2);Nakase, H.(3);Burmester, G.(4);Cohen, S.B.(5);Mease, P.(6);Guttman-Yassky, E.(1);Liu, J.(7);Zhou, W.(7);Ilo, D.(7);Higgins, P.(8);
Created: Friday, 11 February 2022, 3:56 PM
P574 Incidence and indicators of suboptimal response to tumour necrosis factor antagonist therapy in Chinese patients with inflammatory bowel disease: Results from the EXPLORE study
Year: 2020
Source:

ECCO'20 Vienna

Authors:

J. Li1, Z. Li2, P. Hu3, Z. Wen4, Q. Cao5, X. Zou6, Y. Chen7, Y. Wang8, J. Zhong9, X. Shen10, D. Demuth11, O. Fedeeva11, L. Xie12, J. Chen12, J. Qian1

Created: Thursday, 30 January 2020, 10:12 AM
P574: Characterization of plasma inflammatory protein abundance in patients with ulcerative colitis treated with etrasimod: an exploratory analysis of the phase 3 ELEVATE UC 52 and ELEVATE UC 12 trials
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Siegmund, B.(1)*;Ryan, R.(2);Abreu, M.T.(3);Vermeire, S.(4);Dotan, I.(5,6);Goetsch, M.(7);Crosby, C.(8);Woolcott, J.(9);Komori, H.K.(10);Danese, S.(11);
Created: Friday, 14 July 2023, 11:05 AM
P574: Exploring treatment of Crohn’s disease and ulcerative colitis in the Middle East and Northern Africa: An analysis of the HARIR observational cohort study
Year: 2021
Source: ECCO'21 Virtual
Authors: Hamed, W.(1);Salem, O.E.(2);Alharbi, O.(3);,4;Sharaf, M.(5);Taylor, C.(6);Sherief, A.(7);Besar, A.(6);
Created: Wednesday, 2 June 2021, 4:12 PM
P574: IBD patients should be stratified to guide out-of-hospital monitoring: ICHOM-derived outcomes from a dedicated IBD telephone clinic
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

R. K. Fofaria*1, S. Azana1, G. Grande1, P. Naeck-Boolauky1, T. Tyrrell1, N. Arebi1

Created: Friday, 22 February 2019, 9:41 AM
P574: Limitations and difficulties in using anti-TNF-alpha agents in inflammatory bowel disease. A survey of the Italian Group for Inflammatory Bowel Disease (IG-IBD)
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Saibeni S.*1, Bezzio C.1, Armuzzi A.2, Bossa F.3, Calabrese E.4, Caprioli F.5, Daperno M.6, Mocciaro F.7, Orlando A.8, Papi C.9, Rispo A.10, Rizzello F.11 IG-IBD

Created: Wednesday, 20 February 2019, 10:36 AM